Trials / Completed
CompletedNCT00303199
Study of ZIO-101 in Multiple Myeloma
A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZIO-101 (Darinaparsin) | IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-03-15
- Last updated
- 2012-07-19
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00303199. Inclusion in this directory is not an endorsement.